Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Clinical Trial Grant

Duke Scholars

Principal Investigator Jeffrey Melson Clarke Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Grid Therapeutics LLC

Start Date

April 22, 2020

End Date

February 28, 2025

Administered By

Duke Cancer Institute

Awarded By

Grid Therapeutics LLC

Start Date

April 22, 2020

End Date

February 28, 2025